Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992966 | 0.78 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL2646513 | 0.78 | POLB (0.43) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL14671389 | 0.76 | LMNA (0.39) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL9617315 | 0.76 | LMNA (0.39) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL14671697 | 0.76 | CYP3A4 (0.42) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL365852 | 0.76 | CYP3A4 (0.39) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL16761024 | 0.74 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL27501838 | 0.74 | POLB (0.43) | CYP3A4CYP2C9CYP2C19POLBTSHR | |
| SCHEMBL11644166 | 0.70 | CES2 (0.53) | CES2LMNA | |
| SCHEMBL16979607 | 0.70 | CYP3A4 (0.38) | CYP3A4CYP2C9CYP2C19POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210403451-A1 | PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF | Wuxi Biocity Biopharmaceutics Co., Ltd. (CN) | 2021-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210403451-A1 | PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF | WEE1, WEE2, NME1 | CYP3A4 2169/4885CYP2C9 2060/4885CYP2C19 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.